Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Leukemia, Myeloid, Chronic-Phase 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Blast Crisis 10Leukemia 7Leukemia, Myeloid, Accelerated Phase 6Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Recurrence 2Primary Myelofibrosis 2Polycythemia Vera 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

avapritinib 5midostaurin 4masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Phlebotomy 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Dasatinib × Myeloid × Clear all
NCT00979160 2009-09-18

Evaluation of Response of Dasatinib to Treat Mastocytosis

Federico II University

Phase 2 Unknown
30 enrolled
Myeloid

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡